Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
Background Although programmed cell death-1/programmed death-ligand 1 (PD-L1) inhibitors show remarkable antitumor activity, a large portion of patients with cancer, even those with high PD-L1-expressing tumors, do not respond to their effects. Most PD-L1 inhibitors contain modified fragment crystal...
Saved in:
| Main Authors: | Bhumsuk Keam, Miso Kim, Tae Min Kim, Dong-Wan Kim, Dae Seog Heo, Ha-Ram Park, Soyeon Kim, Ji-Eun Park, Seong-Eun Kim, Junsang Doh |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000873.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The combination of SH003 and DTX induces cytotoxic cell infiltration in anti-PD1 resistant lung cancer
by: Yu-Jeong Choi, et al.
Published: (2025-05-01) -
Local injection of CCL19-expressing mesenchymal stem cells augments the therapeutic efficacy of anti-PD-L1 antibody by promoting infiltration of immune cells
by: Mitsuo Oshimura, et al.
Published: (2020-10-01) -
Cell-targeted PD-1 agonists are potent NK-cell inhibitors
by: Harriet C. Pope, et al.
Published: (2025-08-01) -
Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment
by: Nasrah ALKhemeiri, et al.
Published: (2025-05-01) -
Anti-PD-1 antibody enhances homeostatic proliferation–induced antitumor immunity during lymphopenia recovery
by: Zike Yang, et al.
Published: (2025-05-01)